

# Alan F Schatzberg

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2117936/alan-f-schatzberg-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

153  
papers

12,307  
citations

53  
h-index

110  
g-index

168  
ext. papers

14,979  
ext. citations

7.6  
avg, IF

6.44  
L-index

#	Paper	IF	Citations
153	Identification of potential blood biomarkers associated with suicide in major depressive disorder.. <i>Translational Psychiatry</i> , <b>2022</b> , 12, 159	8.6	3
152	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.. <i>Molecular Psychiatry</i> , <b>2021</b> ,	15.1	10
151	Mechanisms of Action of Ketamine and Esketamine. <i>American Journal of Psychiatry</i> , <b>2021</b> , 178, 1130	11.9	1
150	Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , <b>2021</b> , appiajp202120101429	11.9	18
149	Cross-Sectional Associations Among Symptoms of Pain, Irritability, and Depression and How These Symptoms Relate to Social Functioning and Quality of Life: Findings From the EMBARC and STRIDE Studies and the VitalSign6 Project. <i>Journal of Clinical Psychiatry</i> , <b>2021</b> , 82,	4.6	1
148	Comment on "Understanding the Clinical Effects and Mechanisms of Action of Neurosteroids": Response to Rubinow et al. <i>American Journal of Psychiatry</i> , <b>2021</b> , 178, 573-574	11.9	
147	Understanding the Clinical Effects and Mechanisms of Action of Neurosteroids. <i>American Journal of Psychiatry</i> , <b>2021</b> , 178, 221-223	11.9	6
146	Intrinsic reward circuit connectivity profiles underlying symptom and quality of life outcomes following antidepressant medication: a report from the iSPOT-D trial. <i>Neuropsychopharmacology</i> , <b>2021</b> , 46, 809-819	8.7	4
145	Prevalence, Factor Structure, and Heritability of Avoidant Personality Disorder. <i>Journal of Nervous and Mental Disease</i> , <b>2021</b> , 209, 764-772	1.8	1
144	Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. <i>American Journal of Psychiatry</i> , <b>2020</b> , 177, 716-726	11.9	105
143	Multisensory modulation of body ownership in mice. <i>Neuroscience of Consciousness</i> , <b>2020</b> , 2020, niz019	3.3	1
142	Cannabis and the Developing Adolescent Brain. <i>Current Treatment Options in Psychiatry</i> , <b>2020</b> , 7, 144-161	3.1	10
141	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). <i>Molecular Psychiatry</i> , <b>2020</b> , 25, 1592-1603	15.1	125
140	Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. <i>Molecular Psychiatry</i> , <b>2019</b> , 24, 1779-1786	15.1	53
139	Baseline cortisol and the efficacy of antiglucocorticoid treatment in mood disorders: A meta-analysis. <i>Psychoneuroendocrinology</i> , <b>2019</b> , 110, 104420	5	13
138	More Thoughts on Intranasal Esketamine: Response to Drevets et al. <i>American Journal of Psychiatry</i> , <b>2019</b> , 176, 858-859	11.9	5
137	Rigorous Translational Models Are Key to Studying Ketamine's Antidepressant Mechanism: Response to Wang and Kaplin. <i>American Journal of Psychiatry</i> , <b>2019</b> , 176, 412	11.9	1

136	Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect. <i>JAMA Psychiatry</i> , <b>2019</b> , 76, 657-658	14.5	11
135	Genome-wide association study identifies 30 loci associated with bipolar disorder. <i>Nature Genetics</i> , <b>2019</b> , 51, 793-803	36.3	662
134	Scientific Issues Relevant to Improving the Diagnosis, Risk Assessment, and Treatment of Major Depression. <i>American Journal of Psychiatry</i> , <b>2019</b> , 176, 342-347	11.9	7
133	Interpreting Ketamine's Opioid Receptor Dependent Effect: Response to Sanacora. <i>American Journal of Psychiatry</i> , <b>2019</b> , 176, 249-250	11.9	4
132	Target Population, Dose, and Timing Considerations for Understanding Naltrexone's Subjective Effect: Response to Amiaz. <i>American Journal of Psychiatry</i> , <b>2019</b> , 176, 251-252	11.9	3
131	Splice-Break: exploiting an RNA-seq splice junction algorithm to discover mitochondrial DNA deletion breakpoints and analyses of psychiatric disorders. <i>Nucleic Acids Research</i> , <b>2019</b> , 47, e59	20.1	10
130	Prefrontal networks dynamically related to recovery from major depressive disorder: a longitudinal pharmacological fMRI study. <i>Translational Psychiatry</i> , <b>2019</b> , 9, 64	8.6	20
129	Neural cell adhesion molecule peptide mimetics modulate emotionality: pharmacokinetic and behavioral studies in rats and non-human primates. <i>Neuropsychopharmacology</i> , <b>2019</b> , 44, 356-363	8.7	3
128	HPA axis in psychotic major depression and schizophrenia spectrum disorders: Cortisol, clinical symptomatology, and cognition. <i>Schizophrenia Research</i> , <b>2019</b> , 213, 72-79	3.6	17
127	Nonlinear relationship between early life stress exposure and subsequent resilience in monkeys. <i>Scientific Reports</i> , <b>2019</b> , 9, 16232	4.9	8
126	High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression. <i>Brain</i> , <b>2018</b> , 141, e18	11.2	68
125	Corticotropin-releasing factor 1 receptor haplotype and cognitive features of major depression. <i>Translational Psychiatry</i> , <b>2018</b> , 8, 5	8.6	10
124	Combined Analysis of Mifepristone for Psychotic Depression: Plasma Levels Associated With Clinical Response. <i>Biological Psychiatry</i> , <b>2018</b> , 84, 46-54	7.9	36
123	Inference of cell type content from human brain transcriptomic datasets illuminates the effects of age, manner of death, dissection, and psychiatric diagnosis. <i>PLoS ONE</i> , <b>2018</b> , 13, e0200003	3.7	37
122	Connective Tissue Growth Factor Is a Novel Prodepressant. <i>Biological Psychiatry</i> , <b>2018</b> , 84, 555-562	7.9	8
121	Learning to actively cope with stress in female mice. <i>Psychoneuroendocrinology</i> , <b>2018</b> , 96, 78-83	5	4
120	Mitochondrial Complex I Deficiency in Schizophrenia and Bipolar Disorder and Medication Influence. <i>Molecular Neuropsychiatry</i> , <b>2018</b> , 3, 157-169	4.9	22
119	The Black Book of Psychotropic Dosing and Monitoring. <i>Psychopharmacology Bulletin</i> , <b>2018</b> , 48, 64-153	0.9	1

118	Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein. <i>American Journal of Psychiatry</i> , <b>2018</b> , 175, 251-261	11.9	24
117	Empirical evidence of the effect of personality pathology on the outcome of panic disorder. <i>Journal of Psychiatric Research</i> , <b>2018</b> , 107, 42-47	5.2	2
116	Diagnostic differences in verbal learning strategies and verbal memory in patients with mood disorders and psychotic disorders. <i>Psychiatry Research</i> , <b>2018</b> , 269, 733-739	9.9	2
115	Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. <i>American Journal of Psychiatry</i> , <b>2018</b> , 175, 1205-1215	11.9	217
114	More Research Needed on the Association Between Genotype and Antidepressant Response: Response to Fabbri et al. <i>American Journal of Psychiatry</i> , <b>2018</b> , 175, 576-577	11.9	2
113	A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. <i>JAMA Psychiatry</i> , <b>2017</b> , 74, 399-405	14.5	295
112	Resting-state connectivity biomarkers define neurophysiological subtypes of depression. <i>Nature Medicine</i> , <b>2017</b> , 23, 28-38	50.5	972
111	Post-mortem molecular profiling of three psychiatric disorders. <i>Genome Medicine</i> , <b>2017</b> , 9, 72	14.4	79
110	Stress amplifies sex differences in primate prefrontal profiles of gene expression. <i>Biology of Sex Differences</i> , <b>2017</b> , 8, 36	9.3	6
109	Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression. <i>Journal of Clinical Psychopharmacology</i> , <b>2017</b> , 37, 505-511	1.7	23
108	Side Effects to Antidepressant Treatment in Patients With Depression and Comorbid Panic Disorder. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, 433-440	4.6	20
107	Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. <i>Biological Psychiatry</i> , <b>2016</b> , 80, 84-86	7.9	2
106	Eberhard H Uhlenhuth. <i>Neuropsychopharmacology</i> , <b>2016</b> , 41, 3127	8.7	
105	Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression ("RAD") project. <i>BMC Psychiatry</i> , <b>2016</b> , 16, 68	4.2	21
104	Evidence for alterations of the glial syncytial function in major depressive disorder. <i>Journal of Psychiatric Research</i> , <b>2016</b> , 72, 15-21	5.2	57
103	Learning to cope with stress modulates anterior cingulate cortex starburst expression in monkeys and mice. <i>Neurobiology of Learning and Memory</i> , <b>2016</b> , 131, 95-100	3.1	6
102	NMDA antagonist treatment of depression. <i>Current Opinion in Neurobiology</i> , <b>2016</b> , 36, 112-7	7.6	43
101	Striatal dopamine D2/3 receptor regulation by stress inoculation in squirrel monkeys. <i>Neurobiology of Stress</i> , <b>2016</b> , 3, 68-73	7.6	6

100	Human amygdala engagement moderated by early life stress exposure is a biobehavioral target for predicting recovery on antidepressants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 11955-11960	11.5	37
99	Major depressive disorder. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16065	51.1	635
98	The microRNA network is altered in anterior cingulate cortex of patients with unipolar and bipolar depression. <i>Journal of Psychiatric Research</i> , <b>2016</b> , 82, 58-67	5.2	40
97	A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. <i>Neuropsychopharmacology</i> , <b>2015</b> , 40, 1332-42	8.7	71
96	Cognitive and emotional biomarkers of melancholic depression: An iSPOT-D report. <i>Journal of Affective Disorders</i> , <b>2015</b> , 176, 141-50	6.6	21
95	ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial. <i>American Journal of Psychiatry</i> , <b>2015</b> , 172, 751-9	11.9	51
94	Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. <i>American Journal of Psychiatry</i> , <b>2015</b> , 172, 743-50	11.9	106
93	Development of New Psychopharmacological Agents for Depression and Anxiety. <i>Psychiatric Clinics of North America</i> , <b>2015</b> , 38, 379-93	3.1	12
92	Fibroblast growth factor 9 is a novel modulator of negative affect. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 11953-8	11.5	34
91	Decreased hypothalamic functional connectivity with subgenual cortex in psychotic major depression. <i>Neuropsychopharmacology</i> , <b>2015</b> , 40, 849-60	8.7	29
90	fMRI activation during executive function predicts response to cognitive behavioral therapy in older, depressed adults. <i>American Journal of Geriatric Psychiatry</i> , <b>2015</b> , 23, 13-22	6.5	55
89	Anna-Monika Award Lecture, DGPPN Kongress, 2013: the role of the hypothalamic-pituitary-adrenal (HPA) axis in the pathogenesis of psychotic major depression. <i>World Journal of Biological Psychiatry</i> , <b>2015</b> , 16, 2-11	3.8	35
88	Neurobiological signatures of anxiety and depression in resting-state functional magnetic resonance imaging. <i>Biological Psychiatry</i> , <b>2015</b> , 77, 385-93	7.9	96
87	Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?. <i>Neuropsychopharmacology</i> , <b>2015</b> , 40, 259-67	8.7	95
86	Neurobiologic Foundations of Mood Disorders <b>2015</b> , 341-358		
85	Issues encountered in recent attempts to develop novel antidepressant agents. <i>Annals of the New York Academy of Sciences</i> , <b>2015</b> , 1345, 67-73	6.5	7
84	Impairment and distress patterns distinguishing the melancholic depression subtype: an iSPOT-D report. <i>Journal of Affective Disorders</i> , <b>2015</b> , 174, 493-502	6.6	11
83	The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. <i>Journal of Psychiatric Research</i> , <b>2015</b> , 61, 1-12	5.2	90

82	Response to Transdermal Selegiline Smoking Cessation Therapy and Markers in the 15q24 Chromosomal Region. <i>Nicotine and Tobacco Research</i> , <b>2015</b> , 17, 1126-33	4.9	13
81	Mitochondrial mutations in subjects with psychiatric disorders. <i>PLoS ONE</i> , <b>2015</b> , 10, e0127280	3.7	31
80	Coping and glucocorticoid receptor regulation by stress inoculation. <i>Psychoneuroendocrinology</i> , <b>2014</b> , 49, 272-9	5	20
79	Plasma oxytocin concentrations are lower in depressed vs. healthy control women and are independent of cortisol. <i>Journal of Psychiatric Research</i> , <b>2014</b> , 51, 30-6	5.2	66
78	Altered choroid plexus gene expression in major depressive disorder. <i>Frontiers in Human Neuroscience</i> , <b>2014</b> , 8, 238	3.3	33
77	Circadian patterns of gene expression in the human brain and disruption in major depressive disorder. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 9950-5 <sup>11.5</sup>	36 <sup>1</sup>	
76	The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression. <i>Psychoneuroendocrinology</i> , <b>2013</b> , 38, 115-21	5	38
75	Altered brain function underlying verbal memory encoding and retrieval in psychotic major depression. <i>Psychiatry Research - Neuroimaging</i> , <b>2013</b> , 211, 119-26	2.9	27
74	G protein-linked signaling pathways in bipolar and major depressive disorders. <i>Frontiers in Genetics</i> , <b>2013</b> , 4, 297	4.5	43
73	Gene expression changes in the prefrontal cortex, anterior cingulate cortex and nucleus accumbens of mood disorders subjects that committed suicide. <i>PLoS ONE</i> , <b>2012</b> , 7, e35367	3.7	59
72	Aberrant brain activation during a working memory task in psychotic major depression. <i>American Journal of Psychiatry</i> , <b>2011</b> , 168, 173-82	11.9	63
71	Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. <i>Journal of Clinical Psychopharmacology</i> , <b>2010</b> , 30, 135-44	1.7	79
70	A pilot study of the phase angle between cortisol and melatonin in major depression - a potential biomarker?. <i>Journal of Psychiatric Research</i> , <b>2010</b> , 44, 69-74	5.2	47
69	FKBP5 polymorphisms and antidepressant response in geriatric depression. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2010</b> , 153B, 554-560	3.5	44
68	The silver lining of recent effectiveness trials. <i>World Psychiatry</i> , <b>2009</b> , 8, 30-2	14.4	
67	Response to the presidential address. <i>American Journal of Psychiatry</i> , <b>2009</b> , 166, 1105-7	11.9	
66	Effects of major depression diagnosis and cortisol levels on indices of neurocognitive function. <i>Psychoneuroendocrinology</i> , <b>2009</b> , 34, 1012-8	5	45
65	Withdrawal symptoms over time among adolescents in a smoking cessation intervention: do symptoms vary by level of nicotine dependence?. <i>Addictive Behaviors</i> , <b>2009</b> , 34, 1017-22	4.2	15

64	Glucocorticoid antagonists in neuropsychiatric [corrected] disorders. <i>European Journal of Pharmacology</i> , <b>2008</b> , 583, 358-64	5.3	45
63	Achieving remission and favorable outcomes in patients with depression/anxiety and substance use disorders. <i>CNS Spectrums</i> , <b>2008</b> , 13, 10-2	1.8	3
62	The Acute and Post-Discontinuation Effects of a Glucocorticoid Receptor (GR) Antagonist Probe on Sleep and the HPA Axis in Chronic Insomnia: A Pilot Study. <i>Journal of Clinical Sleep Medicine</i> , <b>2008</b> , 04, 235-241	3.1	14
61	Bridging the clinical gap: managing patients with co-occurring mood, anxiety, and alcohol use disorders. Introduction. <i>CNS Spectrums</i> , <b>2008</b> , 13, 3	1.8	2
60	Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. <i>Biological Psychiatry</i> , <b>2007</b> , 62, 429-37	7.9	1650
59	Current issues in the classification of psychotic major depression. <i>Schizophrenia Bulletin</i> , <b>2007</b> , 33, 877-85.	3	82
58	Safety and tolerability of antidepressants: weighing the impact on treatment decisions. <i>Journal of Clinical Psychiatry</i> , <b>2007</b> , 68 Suppl 8, 26-34	4.6	7
57	Detecting psychotic major depression using psychiatric rating scales. <i>Journal of Psychiatric Research</i> , <b>2006</b> , 40, 22-9	5.2	26
56	Clinical and biological effects of mifepristone treatment for psychotic depression. <i>Neuropsychopharmacology</i> , <b>2006</b> , 31, 628-36	8.7	168
55	Reply: Clinical and Biological Effects of Mifepristone Treatment for Psychotic Treatment. <i>Neuropsychopharmacology</i> , <b>2006</b> , 31, 2795-2797	8.7	4
54	A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. <i>American Journal of Geriatric Psychiatry</i> , <b>2006</b> , 14, 361-70	6.5	92
53	Cortisol circadian rhythm alterations in psychotic major depression. <i>Biological Psychiatry</i> , <b>2006</b> , 60, 275-81.	7.9	157
52	The neuropsychological profile of psychotic major depression and its relation to cortisol. <i>Biological Psychiatry</i> , <b>2006</b> , 60, 472-8	7.9	89
51	New paradigm for treating recurrent depression: from symptom control to managing enduring vulnerabilities. <i>CNS Spectrums</i> , <b>2006</b> , 11, 22-7	1.8	4
50	Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67 Suppl 4, 27-30	4.6	18
49	Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. <i>Archives of General Psychiatry</i> , <b>2005</b> , 62, 513-20		110
48	Neuropsychological correlates of psychotic features in major depressive disorders: a review and meta-analysis. <i>Journal of Psychiatric Research</i> , <b>2004</b> , 38, 27-35	5.2	81
47	A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. <i>Journal of Clinical Psychopharmacology</i> , <b>2004</b> , 24, 365-73	1.7	101



46	Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. <i>Journal of Consulting and Clinical Psychology</i> , <b>2004</b> , 72, 729-35	6.5	109
45	Pharmacologic treatments of major depression: are two mechanisms really better than one?. <i>Journal of Clinical Psychiatry</i> , <b>2004</b> , 65 Suppl 4, 3-4	4.6	
44	The relationship of chronic pain and depression. <i>Journal of Clinical Psychiatry</i> , <b>2004</b> , 65 Suppl 12, 3-4	4.6	8
43	Employing pharmacologic treatment of bipolar disorder to greatest effect. <i>Journal of Clinical Psychiatry</i> , <b>2004</b> , 65 Suppl 15, 15-20	4.6	4
42	New approaches to managing psychotic depression. <i>Journal of Clinical Psychiatry</i> , <b>2003</b> , 64 Suppl 1, 19-23	4.6	18
41	Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. <i>Journal of Clinical Psychiatry</i> , <b>2003</b> , 64 Suppl 13, 30-7	4.6	5
40	Introduction: treating depression and anxiety to remission. <i>Journal of Clinical Psychiatry</i> , <b>2003</b> , 64 Suppl 15, 3-4	4.6	1
39	Mesotelencephalic dopamine neurochemical responses to glucocorticoid administration and adrenalectomy in Fischer 344 and Lewis rats. <i>Brain Research</i> , <b>2002</b> , 958, 414-22	3.7	34
38	Pharmacological principles of antidepressant efficacy. <i>Human Psychopharmacology</i> , <b>2002</b> , 17 Suppl 1, S17-22	2.3	29
37	Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone. <i>Journal of Molecular Neuroscience</i> , <b>2002</b> , 19, 201-6	3.3	47
36	Prevalence of depressive episodes with psychotic features in the general population. <i>American Journal of Psychiatry</i> , <b>2002</b> , 159, 1855-61	11.9	180
35	Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. <i>Archives of General Psychiatry</i> , <b>2002</b> , 59, 233-9		97
34	An open label trial of C-1073 (mifepristone) for psychotic major depression. <i>Biological Psychiatry</i> , <b>2002</b> , 52, 386-92	7.9	261
33	Clinical use of nefazodone in major depression: a 6-year perspective. <i>Journal of Clinical Psychiatry</i> , <b>2002</b> , 63 Suppl 1, 18-31	4.6	1
32	Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. <i>American Journal of Geriatric Psychiatry</i> , <b>2002</b> , 10, 541-50	6.5	28
31	Sertraline versus imipramine to prevent relapse in chronic depression. <i>Journal of Affective Disorders</i> , <b>2001</b> , 65, 27-36	6.6	49
30	Corticosteroids and cognition. <i>Journal of Psychiatric Research</i> , <b>2001</b> , 35, 127-45	5.2	210
29	Cortisol activity and cognitive changes in psychotic major depression. <i>American Journal of Psychiatry</i> , <b>2001</b> , 158, 1612-6	11.9	131



28	Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 3568-73	5.6	145
27	Rapid Detection of the C1496G Polymorphism in the CYP2D6 *2 Allele. <i>Clinical Chemistry</i> , <b>2001</b> , 47, 2153-2155	5.5	6
26	Rapid reversal of psychotic depression using mifepristone. <i>Journal of Clinical Psychopharmacology</i> , <b>2001</b> , 21, 516-21	1.7	214
25	Dilative cardiomyopathy leading to congestive heart failure in a male squirrel monkey ( <i>Saimiri sciureus</i> ). <i>Journal of Medical Primatology</i> , <b>2000</b> , 29, 42-5	0.7	17
24	Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain. <i>Journal of Psychiatric Research</i> , <b>2000</b> , 34, 383-92	5.2	196
23	24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. <i>Archives of General Psychiatry</i> , <b>2000</b> , 57, 755-60		160
22	Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. <i>American Journal of Psychiatry</i> , <b>2000</b> , 157, 1095-100	11.9	173
21	A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 1462-70	59.2	985
20	Glucocorticoid effects on mesotelencephalic dopamine neurotransmission. <i>Neuropsychopharmacology</i> , <b>1999</b> , 21, 399-407	8.7	40
19	Hypothalamic-pituitary-adrenal axis effects on plasma homovanillic acid in man. <i>Biological Psychiatry</i> , <b>1999</b> , 45, 222-8	7.9	21
18	Strain differences in mesotelencephalic dopaminergic neuronal regulation between Fischer 344 and Lewis rats. <i>Brain Research</i> , <b>1999</b> , 832, 152-8	3.7	19
17	Postnatal foraging demands alter adrenocortical activity and psychosocial development. <i>Developmental Psychobiology</i> , <b>1998</b> , 32, 285-291	3	79
16	Acute and delayed effects of adrenocorticotrophic hormone on dopamine activity in man. <i>Depression</i> , <b>1994</b> , 2, 292-296		2
15	Acute and delayed effects of corticotropin-releasing hormone on dopamine activity in man. <i>Biological Psychiatry</i> , <b>1994</b> , 36, 616-21	7.9	21
14	Clozapine response and plasma catecholamines and their metabolites. <i>Psychiatry Research</i> , <b>1993</b> , 46, 139-49	9.9	62
13	Relationships between brain CT scan findings and cortisol in psychotic and nonpsychotic depressed patients. <i>Biological Psychiatry</i> , <b>1989</b> , 26, 565-75	7.9	82
12	The roles of glucocorticoid and dopaminergic systems in delusional (psychotic) depression. <i>Annals of the New York Academy of Sciences</i> , <b>1988</b> , 537, 462-71	6.5	36
11	Psychotic and nonpsychotic depressions: I. Comparison of plasma catecholamines and cortisol measures. <i>Psychiatry Research</i> , <b>1987</b> , 20, 143-53	9.9	53

10	Toward a biochemical classification of depressive disorders IX. DST results and platelet MAO activity. <i>British Journal of Psychiatry</i> , <b>1985</b> , 146, 633-7	5.4	13
9	The effects of a single acute dose of dexamethasone on monoamine and metabolite levels in rat brain. <i>Life Sciences</i> , <b>1985</b> , 36, 2491-501	6.8	85
8	A corticosteroid/dopamine hypothesis for psychotic depression and related states. <i>Journal of Psychiatric Research</i> , <b>1985</b> , 19, 57-64	5.2	199
7	Dexamethasone increases plasma free dopamine in man. <i>Journal of Psychiatric Research</i> , <b>1984</b> , 18, 217-23.2		59
6	Commentary 6. <i>Pharmacotherapy</i> , <b>1984</b> , 4, 324-324	5.8	
5	The hypothalamic-pituitary-adrenal axis in alcoholics. <i>Alcoholism: Clinical and Experimental Research</i> , <b>1983</b> , 7, 35-7	3.7	9
4	The dexamethasone suppression test as a discriminator among subtypes of psychotic patients. <i>British Journal of Psychiatry</i> , <b>1982</b> , 141, 471-4	5.4	63
3	Inference of Cell Type Composition from Human Brain Transcriptomic Datasets Illuminates the Effects of Age, Manner of Death, Dissection, and Psychiatric Diagnosis		4
2	Post-mortem molecular profiling of three psychiatric disorders		2
1	Neurobiologic Foundations of Mood Disorders339-353		